Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia
Stephanie von Harsdorf, Lino Lars Teichmann, Axel Benner, Markus P. Radsak et al.
Citations
1 citations
Journal
Blood
Topics
Acute Myeloid Leukemia Research
Field-Weighted Citation Impact (FWCI)
35.41
article
Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia
Stephanie von Harsdorf, Lino Lars Teichmann, Axel Benner, Markus P. Radsak, Gregor Aschauer, W Vogel, Michael Lübbert, A Ganser, Konstanze Döhner, Bernd Hertenstein, David Nachbaur, Lars Bullinger, Katharina S. S. Götze, Lars R. Fransecky, Peter Paschka, Anika Schrade, Walter Fiedler, V I Gaidzik, Jörg Westermann, Roland Schroers, Elisabeth Koller, Michael Heuser, Felicitas R Thol, Ulrich Germing, Maral Saadati, Stefanie Weißhaar, Uwe M Martens, Albert Wölfler, Andrea Corbacioglu, Hans-Joachim Tischler, Daniela Späth, Hartmut Döhner
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Blood
Institutions
Innsbruck Medical University (AT), Universität Hamburg (DE), University of Freiburg (DE), German Cancer Research Center (DE), Johannes Gutenberg University Mainz (DE), Medical University of Graz (AT), Heidelberg University (DE), University Hospital Bonn (DE), University Medical Center Freiburg (DE), Medizinische Hochschule Hannover (DE), University Medical Center of the Johannes Gutenberg University Mainz (DE), Universitätsklinikum Tübingen (DE), Hanusch Hospital (AT), University Medical Center Hamburg-Eppendorf (DE), Universitätsklinikum Knappschaftskrankenhaus Bochum (DE), University Hospital Schleswig-Holstein (DE), University Cancer Center Hamburg (DE), Klinikum Ludwigshafen (DE), AGO Austria (AT), Kliniken Essen-Mitte (DE), University Hospital in Halle (DE), Klinikum Bremen-Mitte (DE), University Hospital Ulm (DE), SLK-Kliniken Heilbronn (DE), Johannes Wesling Klinikum Minden (DE), Heinrich Heine University Düsseldorf (DE), Technical University of Munich (DE), Charité - Universitätsmedizin Berlin (DE), University of Lübeck (DE)
Funders
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Ariad Pharmaceuticals, Celgene, Jazz Pharmaceuticals, BeiGene, Incyte, Syndax Pharmaceuticals, Astellas Pharma, Servier, Swedish Orphan Biovitrum, MorphoSys, Daiichi Sankyo Europe